Recent News

• 12.03.2025 - Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
• 11.17.2025 - Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
• 11.14.2025 - Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
• 11.13.2025 - Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
• 11.13.2025 - Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
• 09.02.2025 - Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

Recent Filings

• 12.02.2025 - 8-K Current report
• 11.21.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 11.13.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 10.24.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 10.16.2025 - 8-K Current report
• 10.06.2025 - 8-K Current report
• 09.08.2025 - 8-K Current report
• 09.02.2025 - 8-K Current report